HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Indegene’s arm to acquire 100% stake in Trilogy Writing & Consulting Inc
Dec-31-2025

Indegene’s wholly owned subsidiary -- Indegene, Inc. (USA) has signed a share purchase agreement (SPA) with Trilogy Writing and Consulting GmbH on December 31, 2025, to acquire 100% equity shares in Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada)), wholly owned subsidiary of Trilogy Writing and Consulting GmbH. The cost of the acquisition is EUR 329,014.00. Trilogy Writing and Consulting GmbH is also the wholly owned subsidiary of the company.

Consequent to the above Trilogy Writing & Consulting Inc. will cease to be the subsidiary of Trilogy Writing and Consulting GmbH and become the wholly owned subsidiary of Indegene, Inc.

Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.

  RELATED NEWS >>